Ra Pharmaceuticals Inc (RARX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7213
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide chemistry platform. Its lead product candidate, RA101495 is a self-administered subcutaneous (SC) injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and lupus nephritis (LN). The company also carries out various preclinical programs intended for the treatment of orphan renal diseases, ocular, autoimmune and CNS diseases; and a non-complement cardiovascular product candidate. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc (RARX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Ra Pharma Raises USD58.5 Million in Series B Financing 10
Equity Offering 12
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 12
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 13
Ra Pharmaceuticals Inc – Key Competitors 14
Ra Pharmaceuticals Inc – Key Employees 15
Ra Pharmaceuticals Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Aug 08, 2018: Ra Pharmaceuticals reports second quarter 2018 financial results 17
May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 18
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 20
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 22
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results 23
May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 25
Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 26
Corporate Communications 28
Sep 25, 2018: Ra Pharma names Aoife M. Brennan, M.B., B.Ch., to Board of Directors 28
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Ra Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Ra Pharma Raises USD58.5 Million in Series B Financing 10
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 12
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 13
Ra Pharmaceuticals Inc, Key Competitors 14
Ra Pharmaceuticals Inc, Key Employees 15

List of Figures
Ra Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Ra Pharmaceuticals Inc (RARX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Seacor Holdings Inc (CKH):石油・ガス:M&Aディール及び事業提携情報
    Summary Seacor Holdings Inc (Seacor) is a diversified holding company that offers domestic and international transportation and logistics and risk management consultancy services. The company operates through business segments such as ocean transportation and logistics services, inland transportatio …
  • Votorantim Energia Ltda:企業の戦略的SWOT分析
    Votorantim Energia Ltda - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Topcon Corp (7732):企業の財務・戦略的SWOT分析
    Topcon Corp (7732) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mithra Pharmaceuticals SA (MITRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • Hologic, Inc.:企業の戦略・SWOT・財務情報
    Hologic, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hologic, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Harbin Electric International Co Ltd:企業の戦略的SWOT分析
    Harbin Electric International Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Sterling Bank Plc:企業の戦略・SWOT・財務分析
    Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Chart Industries Inc (GTLS):企業の財務・戦略的SWOT分析
    Chart Industries Inc (GTLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • L’Oreal SA:戦略・SWOT・企業財務分析
    L'Oreal SA - Strategy, SWOT and Corporate Finance Report Summary L'Oreal SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Nufarm Limited (NUF):企業の財務・戦略的SWOT分析
    Nufarm Limited (NUF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Abeona Therapeutics Inc (ABEO):製薬・医療:M&Aディール及び事業提携情報
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO-102 adeno-associ …
  • Glanbia Nutritionals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Glanbia Nutritionals Inc (Glanbia Nutritionals), a subsidiary of Glanbia plc is a provider of nutritional ingredients, functional ingredients, and customized premix solutions. The company manufactures and markets customized micronutrient blends, vitamins, minerals, amino acids, colors and sp …
  • SpineGuard SA (ALSGD):企業の財務・戦略的SWOT分析
    Summary SpineGuard SA (SpineGuard) is a medical device company that designs, develops and markets spine surgery products. The company offers PediGuard, a device that detects possible vertebral cortex perforation during pedicle preparation. It provides offers screw placement and alerts to surgeon pri …
  • Philippine Long Distance Telephone Company:企業のM&A・事業提携・投資動向
    Philippine Long Distance Telephone Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Philippine Long Distance Telephone Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that o …
  • Kayne Anderson Capital Advisors LP:企業のM&A・事業提携・投資動向
    Kayne Anderson Capital Advisors LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kayne Anderson Capital Advisors LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Ahimsa Industries Limited:戦略・SWOT・企業財務分析
    Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The Boston Beer Company, Inc. (SAM):企業の財務・戦略的SWOT分析
    The Boston Beer Company, Inc. (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Otrum AS:企業の戦略的SWOT分析
    Otrum AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Abivax SA (ABVX):企業の財務・戦略的SWOT分析
    Summary Abivax SA (Abivax) operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆